医学
甲状腺癌
甲状腺
trk受体
癌症
癌症研究
转移
融合基因
病理
内科学
肿瘤科
受体
神经营养素
基因
生物
生物化学
作者
Yanhui Ma,Qi Zhang,Kexin Zhang,Yunzi liang,Fangbing Ren,Jingwen Zhang,Chengxia Kan,Fang Han,Xiaodong Sun
标识
DOI:10.1016/j.critrevonc.2023.103957
摘要
Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase (NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer. NTRK fusion thyroid cancer has unique pathological features such as mixed structure, multiple nodes, lymph node metastasis, and a background of chronic lymphocytic thyroiditis. Currently, RNA-based next-generation sequencing is the gold standard for the detection of NTRK fusions. Tropomyosin receptor kinase inhibitors have shown promising efficacy in patients with NTRK fusion-positive thyroid cancer. Efforts to overcome acquired drug resistance are the focus of research concerning next-generation TRK inhibitors. However, there are no authoritative recommendations or standardized procedures for the diagnosis and treatment of NTRK fusions in thyroid cancer. This review discusses current research progress regarding NTRK fusion-positive thyroid cancer, summarizes the clinicopathological features of the disease, and outlines the current statuses of NTRK fusion detection and targeted therapeutic agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI